----

| x | ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|---|---------------------------------------------------------------------------------|

|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|--------|-------------------------------------------------------------------------------------------|

|   | For the transition period from ___________ to _____________ |
|--------|-------------------------------------------------------------|

| SENESCO TECHNOLOGIES, INC.                             |
|--------------------------------------------------------|
| (Exact name of registrant as specified in its charter) |

| Delaware                                                            |   | 84-1368850                           |
|---------------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |

| 721 Route 202/206, Suite 130, Bridgewater, New Jersey |   | 08807      |
|-------------------------------------------------------|--------|------------|
| (Address of principal executive offices)              |   | (Zip Code) |

| (908) 864-4444                                            |
|-----------------------------------------------------------|
| (Registrant’s telephone number,including area code) |

| Title of each class       |   | Name of each exchange on which registered |
|------------------------------------------|--------|-------------------------------------------------------------------------|
|                                     |   |                                                                    |
| Common Stock, $0.01 par value per share. |   | NYSE Amex                                                               |

| Class                            |   | Number of Shares |
|----------------------------------|--------|----------------------------|
|                             |   |                       |
| Common Stock, $0.01 par value    |   | 79,626,675                 |
| Preferred Stock, $0.01 par value |   | 4,860                      |

----

----

|       | Item   |                                                                                           | Page   |
|------------|--------|------------------------------------------------------------------------------------------------|--------|
|       |   |                                                                                           |   |
| PART III   | 10.    | Directors, Executive Officers and Corporate Governance                                         | 1      |
|       |   |                                                                                           |   |
|       | 11.    | Executive Compensation                                                                         | 8      |
|       |   |                                                                                           |   |
|       | 12.    | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 30     |
|       |   |                                                                                           |   |
|       | 13.    | Certain Relationships and Related Transactions and Director Independence                       | 33     |
|       |   |                                                                                           |   |
|       | 14.    | Principal Accounting Fees and Services                                                         | 35     |
|       |   |                                                                                           |   |
| PART IV    | 15.    | Exhibits and Financial Statement Schedules                                                     | 36     |
|       |   |                                                                                           |   |
| SIGNATURES | 37     |

----

| Item 10. | Directors, Executive Officers and Corporate Governance. |
|----------|---------------------------------------------------------|

| Name                    |   | Age |   | Capacities inWhich Served                                               |   | In CurrentPosition Since |
|-------------------------|--------|-----|--------|-----------------------------------------------------------------------------------|--------|------------------------------------|
| Leslie J. Browne, Ph.D. |   | 61  |   | President and Chief Executive Officer, Director                                   |   | May 2010                           |
| John E. Thompson, Ph.D. |   | 70  |   | Executive Vice President and Chief Scientific Officer, Director    |   | July 2004                          |
| Joel P. Brooks          |   | 52  |   | Chief Financial Officer, Treasurer and Secretary                                  |   | December 2000                      |
| Richard Dondero         |   | 61  |   | Vice President of Research and Development                                        |   | July 2004                          |
| Harlan W. Waksal, M.D.  |   | 58  |   | Chairman of the Board of Directors                                                |   | June 2009                          |
| John. N. Braca (1) (2)  |   | 53  |   | Director                                                                          |   | October 2003                       |
| Christopher Forbes (3)  |   | 60  |   | Director                                                                          |   | January 1999                       |
| Warren J. Isabelle      |   | 59  |   | Director                                                                          |   | June 2009                          |
| Thomas C. Quick (3)     |   | 56  |   | Director                                                                          |   | February 1999                      |
| David Rector (1) (2)    |   | 64  |   | Director                                                                          |   | February 2002                      |
| Rudolf Stalder (2) (3)  |   | 70  |   | Director                                                                          |   | February 1999                      |
| Jack Van Hulst          |   | 72  |   | Director                                                                          |   | January 2007                       |

|   | (1) | Member of the Compensation Committee |
|--------|-----|--------------------------------------|

|   | (2) | Member of the Audit Committee |
|--------|-----|-------------------------------|

|   | (3) | Member of the Nominating and Corporate Governance Committee |
|--------|-----|-------------------------------------------------------------|

----

----

----

----

----

|   | · | honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | full, fair, accurate, timely, and understandable disclosure in reports and documents filed with the SEC and in other public communications made by the Company; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | compliance with applicable governmental laws, rules and regulations; |
|--------|--------|---------------------------------------------------------------------------|

|   | · | the prompt internal reporting of violations of our Code of Ethics to an appropriate person or persons identified in our Code of Ethics; and |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | accountability for adherence to our Code of Ethics. |
|--------|--------|-----------------------------------------------------|

----

|   | · | appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------|

|   | · | overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of certain reports from our independent registered public accounting firm; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------|

|   | · | discussing our risk management policies; |
|--------|--------|------------------------------------------|

|   | · | establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | meeting independently with our independent registered public accounting firm and management; and |
|--------|--------|--------------------------------------------------------------------------------------------------|

|   | · | preparing the audit committee report required by SEC rules. |
|--------|--------|-------------------------------------------------------------|

----

| Item 11. | Executive Compensation. |
|----------|-------------------------|

----

|   | · | annually reviewing and approving, or recommending for approval by our board, the corporate goals and objectives relevant to executive officer compensation; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reviewing and approving, or recommending for approval by our board, the salaries and incentive compensation of our executive officers; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------|

|   | · | preparing the Compensation Committee report, including the Compensation Discussion and Analysis; |
|--------|--------|--------------------------------------------------------------------------------------------------|

|   | · | administering our 2008 Incentive Compensation Plan, or similar stock plan adopted by our stockholders; and |
|--------|--------|------------------------------------------------------------------------------------------------------------|

|   | · | reviewing and making recommendations to our board with respect to director compensation. |
|--------|--------|------------------------------------------------------------------------------------------|

|   | · | to motivate, recruit and retain executives capable of meeting our strategic objectives; |
|--------|--------|-----------------------------------------------------------------------------------------|

|   | · | to provide incentives to ensure superior executive performance and successful financial results for us; and |
|--------|--------|-------------------------------------------------------------------------------------------------------------|

|   | · | to align the interests of executives with the long-term interests of our stockholders. |
|--------|--------|----------------------------------------------------------------------------------------|

|   | · | linking a substantial portion of compensation to our achievement of long-term and short-term financial objectives and the individual’s contribution to the attainment of those objectives; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | providing long-term equity-based incentives and encouraging direct share ownership by executives with the intention of providing incentive-based compensation to encourage a long-term focus on company profitability and stockholder value; and |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | understanding the marketplace and establishing a compensation structure that is adjusted for our position in the marketplace and our current financial condition and limited capital resources. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|   | · | base salary; |
|--------|--------|--------------|

|   | · | annual short-term equity incentives; and |
|--------|--------|------------------------------------------|

|   | · | a continuation of the long-term equity incentive program. |
|--------|--------|-----------------------------------------------------------|

|   | · | base salary; |
|--------|--------|--------------|

|   | · | annual short-term equity incentives; and |
|--------|--------|------------------------------------------|

|   | · | a continuation of the long-term equity incentive program. |
|--------|--------|-----------------------------------------------------------|

----

|            |   |                                             |   | 2011   |    |   | 2010   |   |    | %        |   |
|-----------------|--------|--------------------------------------------------|--------|--------|---------|--------|--------|--------|---------|----------|--------|
| Name            |   | Title                                            |   | Salary |    |   | Salary |   |    | Increase |   |
|            |   |                                             |   |   |    |   |   |   |    |     |   |
| Joel P. Brooks  |   | Chief Financial Officer, Secretary and Treasurer |   | $      | 164,800 |   |   | $      | 160,000 |     |   |   | 3.0 | % |
|            |   |                                             |   |   |    |   |   |   |    |     |   |   |   |   |
| Richard Dondero |   | Vice-President of Research and Development       |   | $      | 147,300 |   |   | $      | 143,000 |     |   |   | 3.0 | % |

|                    |   |                                                  |   | 2012   |    |   | 2011   |   |    | %        |   |
|-------------------------|--------|-------------------------------------------------------|--------|--------|---------|--------|--------|--------|---------|----------|--------|
| Name                    |   | Title                                                 |   | Salary |    |   | Salary |   |    | Increase |   |
| Leslie J. Browne, Ph.D. |   | President and Chief Executive Officer                 |   | $      | 262,500 |   |   | $      | 250,000 |     |   |   | 5.0 | % |
|                    |   |                                                  |   |   |    |   |   |   |    |     |   |   |   |   |
| John E. Thompson, Ph.D. |   | Executive Vice-President and Chief Scientific Officer |   | $      | 67,500  | (1)    |   | $      | 65,000  | (1)      |   |   | 3.8 | % |
|                    |   |                                                  |   |   |    |   |   |   |    |     |   |   |   |   |
| Joel P. Brooks          |   | Chief Financial Officer, Secretary and Treasurer      |   | $      | 170,000 |   |   | $      | 164,800 |     |   |   | 3.0 | % |
|                    |   |                                                  |   |   |    |   |   |   |    |     |   |   |   |   |
| Richard Dondero         |   | Vice-President of Research and Development            |   | $      | 153,200 |   |   | $      | 147,300 |     |   |   | 4.0 | % |

----

|   | · | Contributions relating to the development of our SNS01-T assets: |
|--------|--------|------------------------------------------------------------------|

|   | o | Submit IND for Phase I/II clinical trial; |
|--------|---|-------------------------------------------|

|   | o | Initiate Phase I/II clinical trial; |
|--------|---|-------------------------------------|

|   | o | Plan Phase II clinical trial; |
|--------|---|-------------------------------|

|   | o | Develop SNS01-T development plan to NDA submission; |
|--------|---|-----------------------------------------------------|

|   | · | Contributions relating to finance objectives: |
|--------|--------|-----------------------------------------------|

|   | o | Maintain sufficient capital resources; |
|--------|---|----------------------------------------|

|   | o | Maintain NYSE Amex compliance; |
|--------|---|--------------------------------|

|   | o | Increase shareholder communications and enhance investor relations; |
|--------|---|---------------------------------------------------------------------|

|   | · | Contributions relating to corporate development: |
|--------|--------|--------------------------------------------------|

|   | o | Update corporate strategy; and |
|--------|---|--------------------------------|

|   | o | Re-align our structure to best implement corporate strategies. |
|--------|---|----------------------------------------------------------------|

----

| Leslie J. Browne, Ph.D. |   |   | 725,000 |   |
|-------------------------|--------|--------|---------|--------|
| Joel Brooks             |   |   | 425,000 |   |
| Richard Dondero         |   |   | 425,000 |   |
| John E. Thompson, Ph.D. |   |   | 425,000 |   |

|   | · | Contributions relating to the development of our SNS01-T assets: |
|--------|--------|------------------------------------------------------------------|

|   | o | Demonstrate the pre-clinical effects of SNS01-T in combination with certain approved therapeutic products; |
|--------|---|------------------------------------------------------------------------------------------------------------|

|   | o | Develop an improved SNS01-T formulation; |
|--------|---|------------------------------------------|

|   | o | Complete treatment under the Phase 1b/2a clinical study for SNS01-T in multiple myeloma; and |
|--------|---|----------------------------------------------------------------------------------------------|

|   | o | Plan a clinical study for SNS01-T in B cell cancers in addition to multiple myeloma; |
|--------|---|--------------------------------------------------------------------------------------|

|   | · | Contributions relating to finance objectives: |
|--------|--------|-----------------------------------------------|

|   | o | Maintain sufficient working capital and plan and execute financing activities; and |
|--------|---|------------------------------------------------------------------------------------|

|   | o | Regain and maintain NYSE Amex compliance; |
|--------|---|-------------------------------------------|

|   | · | Contributions relating to corporate development: |
|--------|--------|--------------------------------------------------|

|   | o | Expand product portfolio; and |
|--------|---|-------------------------------|

|   | o | Investigate partnering opportunities. |
|--------|---|---------------------------------------|

----

| Leslie J. Browne, Ph.D. |   |   | 819,000 |   |
|-------------------------|--------|--------|---------|--------|
| Joel Brooks             |   |   | 468,000 |   |
| Richard Dondero         |   |   | 468,000 |   |
| John E. Thompson, Ph.D. |   |   | 468,000 |   |

----

| LTIP Event Milestone                                                                                                                           |   | Percentage ofLTIP RSU andISO Award Pool |   |   | Total Amount of RSUs andISO’s Awarded As a Whole toAll Named Executive Officers |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| First LTIP Event Milestone.The Execution of a  Research Agreement to Conduct Phase I/II Trials at a Research Facility                          |   |                                                             | 20     | %      |                                                                                                                                              |   | 120,000 |   |
| Second LTIP Event Milestone.The Filing and Acceptance by the U.S. FDA of an investigation new drug application, or IND, by the date set by the Committee |   |                                                             | 20     | %      |                                                                                                                                              |   | 120,000 |   |
| Third LTIP Event Milestone.The Successful Completion of Phase I/II Trials Approved by the FDA by the date set by the Committee                           |   |                                                             | 60     | %      |                                                                                                                                              |   | 360,000 |   |

----

| Name                     | Title                                                        |   | Percentage ofTotal RSU’sAwarded UponCompletion of aLTIP EventMilestone |   |   | Number ofRSU’s Awardedupon Completionof First LTIPEvent Milestone |   |   | Number ofRSU’s AwardeduponCompletion ofSecond LTIPEvent Milestone |   |   | Number ofRSU’s AwardeduponCompletion ofThird LTIPEvent Milestone |   |
|--------------------------|--------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------|--------|--------|-------------------------------------------------------------------------------------------------------|--------|--------|--------------------------------------------------------------------------------------------------|--------|--------|-------------------------------------------------------------------------------------------------|--------|
| Joel P. Brooks(1)        | Chief Financial Officer, Treasurer and Secretary             |   |                                                                                                       | 10     | %      |                                                                                                  |   | 10,000 |                                                                                             |   |   | 10,000                                                                                          |   |   |   | 30,000 |   |
| John E. Thompson(2)      | Executive Vice-President and Chief Scientific Officer        |   |                                                                                                       | 25     | %      |                                                                                                  |   | 50,000 |                                                                                             |   |   | 50,000                                                                                          |   |   |   | 150,000 |   |
| Richard Dondero(2)       | Vice-President of Research and Development                   |   |                                                                                                       | 30     | %      |                                                                                                  |   | 60,000 |                                                                                             |   |   | 60,000                                                                                          |   |   |   | 180,000 |   |
| Bruce C. Galton(1) (3)   | Former President and Chief Executive Officer                 |   |                                                                                                       | 25     | %      |                                                                                                  |   | 25,000 |                                                                                             |   |   | 25,000                                                                                          |   |   |   | 75,000 |   |
| Sascha P. Fedyszyn(1)(4) | Former Vice-President of Corporate Development and Secretary |   |                                                                                                       | 10     | %      |                                                                                                  |   | 10,000 |                                                                                             |   |   | 10,000                                                                                          |   |   |   | 30,000 |   |

|   | (1) | Represents RSU’s. |
|--------|-----|-------------------------|

|   | (2) | Represents ISO’s. |
|--------|-----|-------------------------|

|   | (3) | Mr. Galton resigned from Senesco on November 16, 2009 and, thus his awards set forth above, which were unvested at the time of his resignation, were forfeited. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (4) | Mr. Fedyszyn resigned from Senesco on February 1, 2010 and, thus his awards set forth above, which were unvested at the time of his resignation, were forfeited. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | This report is submitted on behalf of the |
|--------|-------------------------------------------|
|   | Compensation Committee                    |
|   | David Rector, Chairman                    |
|   | John N. Braca                             |

----

| Nameand PrincipalPosition |   | Year(1) |   | Salary($)(2) |    |   | Bonus($)(3) |   |   | StockAwards($) (4) |   |   | OptionAwards($) (5) |   |   | Non-EquityIncentivePlanCompensation($) |    |   | Change inPension ValueandNonqualifiedDeferredCompensationEarnings ($) |   |   | All OtherCompensation($) |   |   | Total($) |   |
|--------------------------------|--------|---------|--------|--------------|---------|--------|-------------|--------|--------|-------------------------|--------|--------|--------------------------|--------|--------|----------------------------------------|---------|--------|--------------------------------------------------------------------------------------|--------|--------|-------------------------------|--------|--------|----------|--------|
| (a)                            |   | (b)     |   | (c)          |    |   | (d)         |   |   | (e)                     |   |   | (f)                      |   |   | (g)                                    |    |   | (h)                                                                                  |   |   | (i)                           |   |   | (j)      |   |
| Leslie J. Browne, Ph.D. (6)    |   | 2011    |   | $            | 250,468 |   |        |   | -      |                    |   |   | -                        |   |   | $                                      | 154,425 |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   |   |   | $ | 404,893 |   |
| (President and Chief           |   | 2010    |   | $            | 27,885  |   |        |   | -      |                    |   |   | -                        |   |   | $                                      | 440,000 |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 467,885 |   |
| Executive Officer)             |   | 2009    |   |         | -       |   |        |   | -      |                    |   |   | -                        |   |   |                                   | -       |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   |   | - |   |
| Joel Brooks                    |   | 2011    |   | $            | 165,976 |   |        |   | -      |                    |   | $      | 2,600                    |   |   | $                                      | 90,525  |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 259,101 |   |
| (Chief Financial Officer ,     |   | 2010    |   | $            | 163,306 |   |        | $      | 15,000 |                    |   |   | -                        |   |   | $                                      | 66,000  |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 244,306 |   |
| Secretary and Treasurer)       |   | 2009    |   | $            | 161,986 |   |        |   | -      |                    |   | $      | 16,800                   |   |   |                                   | -       |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 178,786 |   |
| Richard Dondero                |   | 2011    |   | $            | 148,827 |   |        |   | -      |                    |   |   | -                        |   |   | $                                      | 90,525  |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 239,352 |   |
| (Vice-President of             |   | 2010    |   | $            | 146,677 |   |        | $      | 15,000 |                    |   |   | -                        |   |   | $                                      | 66,000  |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 227,677 |   |
| Research)                      |   | 2009    |   | $            | 145,507 |   |        |   | -      |                    |   |   | -                        |   |   | $                                      | 34,960  |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 180,467 |   |
| John E. Thompson Ph.D.         |   | 2011    |   | $            | 65,000  |   |        |   | -      |                    |   |   | -                        |   |   | $                                      | 90,525  |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 155,525 |   |
| (Executive Vice-President      |   | 2010    |   | $            | 65,000  |   |        |   | -      |                    |   |   | -                        |   |   |                                   | -       |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 65,000 |   |
| and Chief Scientific           |   | 2009    |   | $            | 65,000  |   |        |   | -      |                    |   |   | -                        |   |   | $                                      | 22,080  |   |                                                                                 |   | -      |                          |   |   | -        |   |   |   | - |   |   | $ | 87,080 |   |
| Officer)                       |   |    |   |         |    |   |        |   |   |                    |   |   |                     |   |   |                                   |    |   |                                                                                 |   |   |                          |   |   |     |   |   |   |   |   |   |   |   |   |

----

| (1) | Senesco’s fiscal year ends on June 30. |
|-----|----------------------------------------------|

| (2) | Such amount represents actual salary paid, including such amounts deferred in connection with our 401K plan. |
|-----|--------------------------------------------------------------------------------------------------------------|

| (3) | The bonus earned for the fiscal year ended June 30, 2010 was declared and paid in October 2010.  There were no bonuses earned or paid during the fiscal years ended June 30, 2011 and 2009. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|               |   |       |   | Estimated Future Payouts Under Non-Equity IncentivePlan Awards |   |   | Estimated Future Payouts UnderEquity Incentive Plan Awards |   |   | All OtherStockAwards:NumberofSharesof Stock |   |   | All OtherOptionAwards:Number ofSecuritiesUnder-lying |   |   | Exerciseor BasePrice ofOption |   |   | GrantDate FairValue ofEquity |   |
|-------------------------|--------|------------|--------|----------------------------------------------------------------------------------------------|--------|--------|------------------------------------------------------------------------------------------|--------|--------|-------------------------------------------------------|--------|--------|----------------------------------------------------------------|--------|--------|-----------------------------------------|--------|--------|----------------------------------------|--------|
| Name                    |   | GrantDate  |   | Threshold($)                                                                                 |   |   | Target($)                                                                                |   |   | Maximum($)                                            |   |   | Threshold(#)                                                   |   |   | Target(#)                               |   |   | Maximum(#)                             |   |   | or Units(#) |   |   | Options(#) |   |   | Awards($/Sh) |   |   | Awards($)(1) |   |
| (a)                     |   | (b)        |   | (c)                                                                                          |   |   | (d)                                                                                      |   |   | (e)                                                   |   |   | (f)                                                            |   |   | (g)                                     |   |   | (h)                                    |   |   | (i) |   |   | (j) |   |   | (k) |   |   |   |   |
| Leslie J. Browne, Ph.D. |   | 11/17/2010 |   |                                                                                         | -      |   |                                                                                     |   | -      |                                                  |   |   | -                                                              |   |   |                                    | -      |   |                                   |   | - |   |   |   | - |   |   |   | - |   |   |   | 725,000 |   |   | $ | 0.26 |   |   | $ | 154,425 |   |
|                    |   |       |   |                                                                                         |   |   |                                                                                     |   |   |                                                  |   |   |                                                           |   |   |                                    |   |   |                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| John E. Thompson, Ph.D. |   | 11/17/2010 |   |                                                                                         | -      |   |                                                                                     |   | -      |                                                  |   |   | -                                                              |   |   |                                    | -      |   |                                   |   | - |   |   |   | - |   |   |   | - |   |   |   | 425,000 |   |   | $ | 0.26 |   |   | $ | 90,525 |   |
|                    |   |       |   |                                                                                         |   |   |                                                                                     |   |   |                                                  |   |   |                                                           |   |   |                                    |   |   |                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Joel P. Brooks          |   | 11/17/2010 |   |                                                                                         | -      |   |                                                                                     |   | -      |                                                  |   |   | -                                                              |   |   |                                    | -      |   |                                   |   | - |   |   |   | - |   |   |   | - |   |   |   | 425,000 |   |   | $ | 0.26 |   |   | $ | 90,525 |   |
|                    |   |       |   |                                                                                         |   |   |                                                                                     |   |   |                                                  |   |   |                                                           |   |   |                                    |   |   |                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Richard Dondero         |   | 11/17/2010 |   |                                                                                         | -      |   |                                                                                     |   | -      |                                                  |   |   | -                                                              |   |   |                                    | -      |   |                                   |   | - |   |   |   | - |   |   |   | - |   |   |   | 425,000 |   |   | $ | 0.26 |   |   | $ | 90,525 |   |

----

----

|         |   | Option Awards                                                       |    | Stock Awards |                                                                        |
|-------------------|--------|--------------------------------------------------------------------------|---------|-------------------|-----------------------------------------------------------------------------|
| Name              |   | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Exercisable |    |              | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Unexer-cisable |   |   | Equity IncentivePlan Awards:Number ofSecuritiesUnderlyingUnexercisedUnearnedOptions (#) |   |   | OptionExercisePrice ($) |   | OptionExpirationDate |   | Number ofShares orUnits of StockThat Have NotVested (#) |   |   | MarketValue ofShares orUnits ofStock ThatHave NotVested ($) |   |   | EquityIncentive PlanAwards:Number ofUnearnedShares, Units orOther RightsThat Have NotVested (#) |   |   | Equity IncentivePlan Awards:Market or PayoutValue ofUnearned Shares,Units or OtherRights That HaveNot Vested ($) |   |
| (a)               |   | (b)                                                                      |    |              | (c)                                                                         |   |   | (d) |   |   | (e) |   | (f) |   | (g) |   |   | (h) |   |   | (i) |   |   | (j) |   |
| Leslie J. Browne, |   |                                                                     | -       |              |                                                                        |   | - |   |   |   | 725,000 | (1) |   | $ | 0.26 |   | 11/17/2020 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Ph.D.             |   |                                                                     | 270,833 |              |                                                                        |   | - |   |   |   | 729,167 | (2) |   | $ | 0.55 |   | 5/25/2020 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     |    |              |                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Joel P. Brooks    |   |                                                                     | -       |              |                                                                        |   | - |   |   |   | 425,000 | (1) |   | $ | 0.26 |   | 11/17/2020 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 180,000 | (3)               |                                                                        |   | - |   |   |   | 120,000 | (3) |   | $ | 0.29 |   | 2/19/2020 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 25,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 2.25 |   | 12/01/2010 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 15,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 2.15 |   | 11/01/2011 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 12,500  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 1.65 |   | 10/09/2012 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 20,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 2.16 |   | 06/19/2013 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 15,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 3.15 |   | 12/16/2013 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 20,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 3.45 |   | 12/16/2014 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 25,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 1.40 |   | 12/14/2015 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 25,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 1.08 |   | 12/14/2016 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     |    |              |                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Richard           |   |                                                                     | -       |              |                                                                        |   | - |   |   |   | 425,000 | (1) |   | $ | 0.26 |   | 11/17/2020 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Dondero           |   |                                                                     | 180,000 | (3)               |                                                                        |   | - |   |   |   | 120,000 | (3) |   | $ | 0.29 |   | 2/19/2020 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 10,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 3.45 |   | 12/16/2014 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 25,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 1.40 |   | 12/14/2015 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 25,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 1.08 |   | 12/14/2016 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 71,924  | (5)               |                                                                        |   | - |   |   |   | - |   |   | $ | 0.99 |   | 12/13/2017 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 60,000  | (5)               |                                                                        |   | - |   |   |   | - |   |   | $ | 0.99 |   | 12/13/2017 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 76,000  | (5)               |                                                                        |   | - |   |   |   | - |   |   | $ | 0.60 |   | 11/19/2018 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     |    |              |                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| John E.           |   |                                                                     | -       |              |                                                                        |   | - |   |   |   | 425,000 | (1) |   | $ | 0.26 |   | 11/17/2020 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Thompson          |   |                                                                     | 80,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 2.05 |   | 12/01/2011 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Ph.D.             |   |                                                                     | 20,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 2.35 |   | 01/07/2013 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 20,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 3.15 |   | 12/16/2013 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 55,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 3.45 |   | 12/16/2014 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 20,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 1.40 |   | 12/14/2015 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 25,000  | (4)               |                                                                        |   | - |   |   |   | - |   |   | $ | 1.08 |   | 12/14/2016 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 52,676  | (5)               |                                                                        |   | - |   |   |   | - |   |   | $ | 0.99 |   | 12/13/2017 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 50,000  | (5)               |                                                                        |   | - |   |   |   | - |   |   | $ | 0.99 |   | 12/13/2017 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|              |   |                                                                     | 48,000  | (5)               |                                                                        |   | - |   |   |   | - |   |   | $ | 0.60 |   | 11/19/2018 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |

| (1) | One-quarter of such options will vest on the first anniversary of the date of grant with one-thirty-sixth of the balance vesting each month thereafter. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | One-quarter of such options vested on the first anniversary of the date of grant with one-thirty-sixth of the balance vesting each month thereafter. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | 60,000 of such options vested on the date of grant and an additional 60,000 of such options vested on each of June 30, 2010 and June 30, 2011.  An additional 60,000 of such options will vest on each of June 30, 2012 and June 30, 2013. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | One-third of such options vested on the date of grant and an additional one-third of such options vested on each of the first and second anniversary of the date of grant. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Such amounts consist of performance based options which vested upon the achievement of certain milestones under our long-term incentive plan. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|

----

|                    |   | OptionAwards         |    |   |       |   |    | StockAwards          |   |   |       |   |
|-------------------------|--------|----------------------|---------|--------|------------|--------|---------|----------------------|--------|--------|------------|--------|
|                    |   | Number ofShares |    |   | Value      |   |    | Number ofShares |   |   | Value      |   |
|                    |   | Acquiredon           |    |   | Realizedon |   |    | Acquiredon           |   |   | Realizedon |   |
|                    |   | Exercise             |    |   | Exercise   |   |    | Vesting              |   |   | Vesting    |   |
| Name                    |   | (#)                  |    |   | ($)        |   |    | (#)                  |   |   | ($)(1)     |   |
| (a)                     |   | (b)                  |    |   | (c)        |   |    | (d)                  |   |   | (e)        |   |
|                    |   |                 |    |   |       |   |    |                 |   |   |       |   |
| Leslie J. Browne, Ph.D. |   |                 | — |   |       |   | — |                 |   |   | 270,833    |   |   | $ | 73,125 |   |
|                    |   |                 |    |   |       |   |    |                 |   |   |       |   |   |   |   |   |
| Joel P. Brooks          |   |                 | — |   |       |   | — |                 |   |   | 60,000     |   |   | $ | 16,800 |   |
|                    |   |                 |    |   |       |   |    |                 |   |   |       |   |   |   |   |   |
| Richard Dondero         |   |                 | — |   |       |   | — |                 |   |   | 60,000     |   |   | $ | 16,800 |   |
|                    |   |                 |    |   |       |   |    |                 |   |   |       |   |   |   |   |   |
| John E. Thompson, Ph.D. |   |                 | — |   |       |   | — |                 |   |   | —    |   |   |   | — |   |

| (1) | Such amounts in this column were calculated by multiplying the number in column (d) by the closing price on the date of vesting. |
|-----|----------------------------------------------------------------------------------------------------------------------------------|

----

| Director               |   | Total # of OptionsGranted |    |
|------------------------|--------|------------------------------------------|---------|
| Harlan W. Waksal, M.D. |   |                                     | 305,000 | (1) |
| Rudolf Stalder         |   |                                     | 155,000 | (1) |
| Rudolf Stalder         |   |                                     | 300,000 | (2) |
| Christopher Forbes     |   |                                     | 190,000 | (1) |
| Thomas C. Quick        |   |                                     | 155,000 | (1) |
| John N. Braca          |   |                                     | 230,000 | (1) |
| David Rector           |   |                                     | 230,000 | (1) |
| Jack Van Hulst         |   |                                     | 155,000 | (1) |
| Warren J. Isabelle     |   |                                     | 155,000 | (1) |

----

----

| Annual (Base) Retainer                                         |   | $      | 10,000 |   |
|----------------------------------------------------------------|--------|--------|--------|--------|
| Per Scheduled Board Meeting Fee                                |   | $      | 1,500  | (1)    |
| Per Committee Meeting Fee                                      |   | $      | 750    | (2)    |
| Additional Annual Retainer:                                    |   |   |   |   |
| Chairman of the Board                                          |   | $      | 5,000  |   |
| Audit Committee Chair                                          |   | $      | 3,500  |   |
| Compensation Committee Chair                                   |   | $      | 3,500  |   |
| Nominating and Corporate Governance Committee Chair            |   | $      | 1,500  |   |
| Non-Chair Committee Member Additional Retainer(All Committees) |   | $      | 1,000  |   |
| Maximum Per Diem For All Meetings                              |   | $      | 2,000  |   |

----

|   | (1) | $750 for telephonic meetings (less than 30 minutes: $375). |
|--------|-----|------------------------------------------------------------|

|   | (2) | $375 for telephonic meetings. |
|--------|-----|-------------------------------|

----

| Name                   |   | FeesEarnedor Paidin Cash($) |    |   | StockAwards($) |   |    | OptionAwards (1)($) |   |   | Non-EquityIncentive PlanCompensation($) |   |   | Change inPension ValueandNonqualifiedDeferredCompensationEarnings |    |   | All OtherCompensation($) |   |    | Total ($) |   |
|------------------------|--------|---------------------------------------|---------|--------|----------------|--------|---------|--------------------------|--------|--------|----------------------------------------------|--------|--------|-----------------------------------------------------------------------------|---------|--------|-------------------------------|--------|---------|----------------|--------|
| (a)                    |   | (b)                                   |    |   | (c)            |   |    | (d)                      |   |   | (e)                                          |   |   | (f)                                                                         |    |   | (g)                           |   |    | (h)            |   |
| Rudolf Stalder         |   |                                  | — |   |           |   | — |                     |   | $      | 52,366                                       |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 52,366 |   |
| Christopher Forbes     |   |                                  | — |   |           |   | — |                     |   | $      | 53,125                                       |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 53,125 |   |
| Thomas C. Quick        |   |                                  | — |   |           |   | — |                     |   | $      | 47,536                                       |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 47,536 |   |
| John N. Braca          |   | $                                     | 14,500  |   |           |   | — |                     |   | $      | 50,530                                       |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 65,030 |   |
| David Rector           |   | $                                     | 14,500  |   |           |   | — |                     |   | $      | 49,353                                       |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 63,853 |   |
| Jack Van Hulst         |   |                                  | — |   |           |   | — |                     |   | $      | 63,009                                       |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 63,009 |   |
| Harlan W. Waksal, M.D. |   |                                  | — |   |           |   | — |                     |   | $      | 188,097                                      |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 188,097 |   |
| Warren J. Isabelle     |   | $                                     | 17,125  |   |           |   | — |                     |   | $      | 20,400                                       |   |   |                                                                        | — |   |                          |   | — |           |   |   | — |   |   | $ | 37,525 |   |

----

|   | (1) | Represents the aggregate grant date fair value for stock options granted in Fiscal 2011 as described below calculated in accordance with the FASB ASC Topic 718 and were not adjusted to take into account any estimated forfeitures. For information regarding assumptions underlying the FASB ASC Topic 718 valuation of equity awards, see Notes 2 and 11 of the Notes to the Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended June 30, 2011.  Does not include the aggregate grant date fair value for stock options granted on September 30, 2011. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Director               |   | Option GrantDate        |   | ExercisePrice |   |   | # of Shares |   |    | Grant Date FairValue |   |
|------------------------|--------|------------------------------|--------|---------------|--------|--------|-----------------------|--------|---------|--------------------------------|--------|
|                   |   | 5/17/2011                    |   | $             | 0.27   |   |                  |   | 48,148  |                           |   | $ | 10,207 |   |
| Rudolf Stalder         |   | 2/14/2011                    |   | $             | 0.29   |   |                  |   | 31,896  |                           |   | $ | 7,113 |   |
|                   |   | 11/17/2010                   |   | $             | 0.26   |   |                  |   | 171,792 |                           |   | $ | 35,046 |   |
|                   |   |                         |   |          |   |   |                  |   |    |                           |   |   |   |   |
|                   |   | 5/17/2011                    |   | $             | 0.30   |   |                  |   | 37,962  |                           |   | $ | 7,668 |   |
| Christopher Forbes     |   | 2/14/2011                    |   | $             | 0.32   |   |                  |   | 32,758  |                           |   | $ | 7,207 |   |
|                   |   | 11/17/2010                   |   | $             | 0.29   |   |                  |   | 192,308 |                           |   | $ | 38,250 |   |
|                   |   |                         |   |          |   |   |                  |   |    |                           |   |   |   |   |
|                   |   | 5/17/2011                    |   | $             | 0.27   |   |                  |   | 28,704  |                           |   | $ | 6,085 |   |
| Thomas C. Quick        |   | 2/14/2011                    |   | $             | 0.29   |   |                  |   | 29,310  |                           |   | $ | 6,536 |   |
|                   |   | 11/17/2010                   |   | $             | 0.26   |   |                  |   | 171,154 |                           |   | $ | 34,915 |   |
|                   |   |                         |   |          |   |   |                  |   |    |                           |   |   |   |   |
|                   |   | 5/17/2011                    |   | $             | 0.27   |   |                  |   | 27,778  |                           |   | $ | 5,889 |   |
| John N. Braca          |   | 2/14/2011                    |   | $             | 0.29   |   |                  |   | 18,104  |                           |   | $ | 4,037 |   |
|                   |   | 11/17/2010                   |   | $             | 0.26   |   |                  |   | 199,038 |                           |   | $ | 40,604 |   |
|                   |   |                         |   |          |   |   |                  |   |    |                           |   |   |   |   |
|                   |   | 5/17/2011                    |   | $             | 0.27   |   |                  |   | 27,778  |                           |   | $ | 5,889 |   |
| David Rector           |   | 2/14/2011                    |   | $             | 0.29   |   |                  |   | 18,104  |                           |   | $ | 4,037 |   |
|                   |   | 11/17/2010                   |   | $             | 0.26   |   |                  |   | 193,269 |                           |   | $ | 39,427 |   |
|                   |   |                         |   |          |   |   |                  |   |    |                           |   |   |   |   |
|                   |   | 5/17/2011                    |   | $             | 0.27   |   |                  |   | 32,408  |                           |   | $ | 6,870 |   |
| Jack Van Hulst         |   | 2/14/2011                    |   | $             | 0.29   |   |                  |   | 32,758  |                           |   | $ | 7,305 |   |
|                   |   | 11/17/2010                   |   | $             | 0.26   |   |                  |   | 237,177 |                           |   | $ | 48,834 |   |
|                   |   |                         |   |          |   |   |                  |   |    |                           |   |   |   |   |
|                   |   | 5/17/2011                    |   | $             | 0.27   |   |                  |   | 51,852  |                           |   | $ | 10,993 |   |
| Harlan W. Waksal, M.D. |   | 2/14/2011                    |   | $             | 0.29   |   |                  |   | 45,690  |                           |   | $ | 10,189 |   |
|                   |   | 11/17/2010                   |   | $             | 0.26   |   |                  |   | 796,154 |                           |   | $ | 166,915 |   |
|                   |   |                         |   |          |   |   |                  |   |    |                           |   |   |   |   |
| Warren J. Isabelle*    |   |    11/17/2010 |   | $             | 0.26   |   |                  |   | 100,000 |                           |   | $ | 20,400 |   |

----

| Director               |   | Total # of OptionsOutstanding |      |
|------------------------|--------|----------------------------------------------|-----------|
| Rudolf Stalder         |   |                                         | 1,161,787 |   |
| Christopher Forbes     |   |                                         | 741,239   |   |
| Thomas C. Quick        |   |                                         | 600,373   |   |
| John N. Braca          |   |                                         | 714,489   |   |
| David Rector           |   |                                         | 691,797   |   |
| Jack Van Hulst         |   |                                         | 680,375   |   |
| Harlan W. Waksal, M.D. |   |                                         | 1,157,654 |   |
| Warren J. Isabelle     |   |                                         | 125,000   |   |

----

----

| Name and Address of Beneficial Owner (1)                                                                 |   | Amount and Nature ofBeneficial Ownership(2) |       |   | Percentof Class(3) |   |
|----------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------|------------|--------|-------------------------|--------|
|                                                                                                                                   |   |                                                            |       |   |                    |   |
| (i)       Certain Beneficial Owners:                                                                |   |                                                            |       |   |                    |   |
|                                                                                                                                   |   |                                                            |       |   |                    |   |   |   |
| Partlet Holdings Ltd.International House, 1st Floor41, The ParadeSt. Helier, JERSEY, Channel Islands                                   |   |                                                            | 7,961,309  | (4)    |                    |   | 9.6 | % |
|                                                                                                                                   |   |                                                            |       |   |                    |   |   |   |
| Defiance Fund, Ltd.488 Madison Avenue12th FloorNew York, NY 10022                                                                      |   |                                                            | 5,368,195  | (5)    |                    |   | 6.5 | % |
|                                                                                                                                   |   |                                                            |       |   |                    |   |   |   |
| (ii)      Directors (which includes all nominees), Named Executive Officers and Chief Executive Officer: |   |                                                            |       |   |                    |   |   |   |
| Harlan W. Waksal, M.D.                                                                                                                 |   |                                                            | 3,794,696  | (6)    |                    |   | 4.5 | % |
| John N. Braca                                                                                                                          |   |                                                            | 1,038,012  | (7)    |                    |   | 1.3 | % |
| Jack Van Hulst                                                                                                                         |   |                                                            | 788,357    | (8)    |                    |   | 1.0 | % |
| Christopher Forbes                                                                                                                     |   |                                                            | 19,678,133 | (9)    |                    |   | 21.3 | % |
| Warren J. Isabelle                                                                                                                     |   |                                                            | 371,823    | (10)   |                    |   | * |   |
| Thomas C. Quick                                                                                                                        |   |                                                            | 1,896,208  | (11)   |                    |   | 2.3 | % |
| David Rector                                                                                                                           |   |                                                            | 1,215,408  | (12)   |                    |   | 1.5 | % |
| Rudolf Stalder                                                                                                                         |   |                                                            | 2,882,287  | (13)   |                    |   | 3.5 | % |
| John E. Thompson, Ph.D.                                                                                                                |   |                                                            | 1,057,780  | (14)   |                    |   | 1.3 | % |
| Joel P. Brooks                                                                                                                         |   |                                                            | 478,479    | (15)   |                    |   | * |   |
| Richard Dondero                                                                                                                        |   |                                                            | 563,028    | (16)   |                    |   | * |   |
| Leslie J. Browne, Ph.D.                                                                                                                |   |                                                            | 580,354    | (17)   |                    |   | * |   |
| (iii)     All Directors and current executive officers as a group (12 persons)                                |   |                                                            | 34,344,565 | (18)   |                    |   | 33.3 | % |

----

|   | (1) | Unless otherwise provided, all addresses should be care of Senesco Technologies, Inc., 721 Route 202/206, Suite 130, Bridgewater, New Jersey 08807. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | Except as otherwise indicated, all shares of common stock are beneficially owned and sole investment and voting power is held by the persons named. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (3) | Applicable percentage of ownership is based on 80,777,097 shares of our common stock outstanding as of October 15, 2011, plus any common stock equivalents and options or warrants held by such holder which are presently or will become exercisable within sixty (60) days after October 15, 2011. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (4) | Includes 3,618,056 shares of common stock issuable pursuant to presently exercisable warrants. |
|--------|-----|------------------------------------------------------------------------------------------------|

|   | (5) | Includes 1,562,500 shares of common stock issuable pursuant to presently exercisable warrants.  Per Form 13G filed on May 20, 2011. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|

|   | (6) | Includes 2,112,904 shares of common stock issuable pursuant to presently exercisable warrants and options or options which will become exercisable within sixty (60) days after October 15, 2011. Also includes 740,740 shares of common stock issuable pursuant to the conversion of convertible preferred stock at a conversion rate of $0.27.   Excludes 517,083 shares of common stock issuable pursuant to options which become exercisable after sixty (60) days from October 15, 2011. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (7) | Includes 900,048 shares of common stock issuable pursuant to presently exercisable warrants and options or options which will become exercisable within sixty (60) days after October 15, 2011.  Excludes 115,000 shares of common stock issuable pursuant to options which become exercisable after sixty (60) days from October 15, 2011. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (8) | Includes 748,289 shares of common stock issuable pursuant to presently exercisable warrants and options or options which will become exercisable within sixty (60) days after October 15, 2011.   Excludes 113,958 shares of common stock issuable pursuant to options which become exercisable after sixty (60) days from October 15, 2011. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (9) | Includes 7,927,716 shares of common stock issuable pursuant to presently exercisable warrants and options or options which will become exercisable within sixty (60) days after October 15, 2011.  Also includes 3,703,704 shares of common stock issuable pursuant to the conversion of convertible preferred stock at a conversion rate of $0.27.  Excludes 95,000 shares of common stock issuable pursuant to options which become exercisable after sixty (60) days from October 15, 2011. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (10) | Includes 270,059 shares of common stock issuable pursuant to presently exercisable warrants and options or options which will become exercisable within sixty (60) days after October 15, 2011. Excludes 77,500 shares of common stock issuable pursuant to options which become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (11) | Represents 675,173 shares of common stock and 403,428 shares of common stock issuable pursuant to warrants issued to Thomas C. Quick Charitable Foundation, of which Mr. Quick is the sole trustee.  Represents 139,734 shares of common stock and 677,873 shares of common stock issuable pursuant to presently exercisable options or options which will become exercisable within sixty (60) days after October 15, 2011 issued to Thomas C. Quick.  Excludes 77,500 shares of common stock issuable pursuant to options issued to Thomas C. Quick which become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (12) | Includes 944,662 shares of common stock issuable pursuant to presently exercisable warrants and options or options which will become exercisable within sixty (60) days after October 15, 2011. Excludes 115,000 shares of common stock issuable pursuant to options which become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (13) | Includes 1,828,349 shares of common stock issuable pursuant to presently exercisable warrants and options or options which will become exercisable within sixty (60) days after October 15, 2011.  Excludes 377,500 shares of common stock issuable pursuant to options which become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (14) | Represents 572,000 shares of common stock held by 2091794 Ontario Ltd., of which Dr. Thompson is the sole owner, and 485,780 shares of common stock issuable pursuant to presently exercisable options or options which will become exercisable within sixty (60) days after October 15, 2011 issued to John E. Thompson, Ph.D.  Excludes 777,896 shares of common issuable pursuant to options which will become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (15) | Includes 427,604 shares of common stock issuable pursuant to presently exercisable options or options which will become exercisable within sixty (60) days after October 15, 2011.  Excludes 897,896 shares of common stock issuable pursuant to options which will become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (16) | Includes 563,028 shares of common stock issuable pursuant to presently exercisable options or options which will become exercisable within sixty (60) days after October 15, 2011.  Excludes 897,896 shares of common stock issuable pursuant to options which will become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (17) | Includes 571,354 shares of common stock issuable pursuant to presently exercisable options or options which will become exercisable within sixty (60) days after October 15, 2011.  Excludes 1,972,646 shares of common stock issuable pursuant to options which will become exercisable after sixty (60) days from October 15, 2011. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (18) | See Notes 6 through 17. |
|--------|------|-------------------------|

|                                                       |   | Number of securitiesto be issued upon exercise of outstanding options, warrants and rights |       |   | Weighted-averageexercise price of outstanding options, warrants and rights |   |    | Number of securities remainingavailable for future issuanceunder equity compensation plans |   |
|------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|---------------------------------------------------------------------------------------------------------------|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------|--------|
| Stock Option plans approved by security holders            |   |                                                                                                                                                   | 11,348,314 | (1)    |                                                                                                          | $      | 0.78    |                                                                                                                                    |   |   | 14,643,289 | (2) |
| Equity compensation plans not approved by security holders |   |                                                                                                                                                   | —    |   |                                                                                                          |   | — |                                                                                                                                    |   |   | — |   |
| Total                                                      |   |                                                                                                                                                   | 11,348,314 | (1)    |                                                                                                          | $      | 0.78    |                                                                                                                                    |   |   | 14,643,289 | (2) |

----

|   | (1) | Issued pursuant to our 1998 Stock Plan and 2008 Stock Plan. |
|--------|-----|-------------------------------------------------------------|

|   | (2) | Available for future issuance pursuant to our 2008 Stock Plan. |
|--------|-----|----------------------------------------------------------------|

----

| Date of Grant |   | # of Warrant /Option Shares |   |   | Exercise Price |   |   | Value of Serviceson Date of Grant |   |   | # of WarrantShares Vested |   |
|-------------------------|--------|-------------------------------------------------|--------|--------|---------------------|--------|--------|------------------------------------------------------------|--------|--------|------------------------------------------|--------|
| November 17, 2010       |   |                                            | 5,000  |   |                | $      | 0.26   |                                                       |   | $      | 1,300                                    |   |   |   | 1,667 |   |
| September 30, 2011      |   |                                            | 10,000 |   |                | $      | 0.23   |                                                       |   | $      | 1,780                                    |   |   |   | 3,333 |   |

----

|   | · | the related person’s interest in the transaction; |
|--------|--------|---------------------------------------------------------|

|   | · | the approximate dollar value of the transaction; |
|--------|--------|--------------------------------------------------|

|   | · | whether the transaction was undertaken in the ordinary course of our business; |
|--------|--------|--------------------------------------------------------------------------------|

|   | · | whether the terms of the transaction are no less favorable to us than terms that we could have reached with an unrelated third party; and |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | the purpose and potential benefit to us of the transaction. |
|--------|--------|-------------------------------------------------------------|

----

|               |   | 2011   |    |   | 2010   |   |
|--------------------|--------|--------|---------|--------|--------|--------|
| Audit Fees         |   | $      | 98,500  |   |   | $      | 91,000 |   |
| Audit Related Fees |   |   | 38,500  |   |   |   | 8,500 |   |
| Tax Fees           |   |   | -       |   |   |   | - |   |
| All Other Fees     |   |   | -       |   |   |   | - |   |
| Total Fees         |   | $      | 137,000 |   |   | $      | 99,500 |   |

----

----

| SENESCO TECHNOLOGIES, INC. |
|----------------------------|
|                       |   |
| By:                        | /s/ Leslie J. Browne |
|                       | Leslie J. Browne, Ph.D., President and |
|                       | Chief Executive Officer |
|                       | (principal executive officer) |
|                       |   |
| By:                        | /s/ Joel Brooks |
|                       | Joel Brooks, Chief Financial Officer, |
|                       | Secretary and Treasurer |
|                       | (principal financial and accountingofficer) |

----

| Signature                   |         | Title                                      |         | Date             |
|-----------------------------|--------------|--------------------------------------------|--------------|------------------|
|                        |         |                                       |         |             |
| /s/ Harlan W. Waksal, M.D.  |         | Chairman and Director                      |         | October 24, 2011 |
| Harlan W. Waksal, M.D.      |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ Leslie J. Browne, Ph.D. |         | President, Chief Executive Officer         |         | October 24, 2011 |
| Leslie J. Browne, Ph.D.     |         | and Director (principal executive officer) |         |             |
|                        |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ Joel Brooks             |         | Chief Financial Officer, Secretary         |         | October 24, 2011 |
| Joel Brooks                 |         | and Treasurer (principal financial         |         |             |
|                        |         | and accounting officer)                    |         |             |
|                        |         |                                       |         |             |
| /s/ John E. Thompson, Ph.D. |         | Executive Vice President, Chief            |         | October 24, 2011 |
| John E. Thompson            |         | Scientific Officer and Director            |         |             |
|                        |         |                                       |         |             |
| /s/ John Braca              |         | Director                                   |         | October 24, 2011 |
| John Braca                  |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ Christopher Forbes      |         | Director                                   |         | October 24, 2011 |
| Christopher Forbes          |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ Warren J. Isabelle      |         | Director                                   |         | October 24, 2011 |
| Warren J. Isabelle          |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ Thomas C. Quick         |         | Director                                   |         | October 24, 2011 |
| Thomas C. Quick             |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ David Rector            |         | Director                                   |         | October 24, 2011 |
| David Rector                |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ Rudolf Stalder          |         | Director                                   |         | October 24, 2011 |
| Rudolf Stalder              |         |                                       |         |             |
|                        |         |                                       |         |             |
| /s/ Jack Van Hulst          |         | Director                                   |         | October 24, 2011 |
| Jack Van Hulst              |    |                                       |    |             |

----

| ExhibitNo.   |   | Description of Exhibit                                                                                           |
|--------------|--------|----------------------------------------------------------------------------------------------------------------------------|
|         |   |                                                                                                                       |
| 31.1 † |   | Certification of the principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                |
|         |   |                                                                                                                       |
| 31.2 † |   | Certification of the principal financial and accounting officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|         |   |                                                                                                                       |
| 32.1 † |   | Certification of the principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                |
|         |   |                                                                                                                       |
| 32.2 † |   | Certification of the principal financial and accounting officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

| † | Filed herewith. |
|---------|-----------------|

----